Rescuing  ||| S:0 E:9 ||| NNP
failed  ||| S:9 E:16 ||| VBD
oral  ||| S:16 E:21 ||| JJ
implants  ||| S:21 E:30 ||| NN
via  ||| S:30 E:34 ||| IN
Wnt  ||| S:34 E:38 ||| NNP
activation  ||| S:38 E:49 ||| FW
Implant  ||| S:49 E:57 ||| FW
osseointegration  ||| S:57 E:74 ||| FW
is  ||| S:74 E:77 ||| VBZ
not  ||| S:77 E:81 ||| RB
always  ||| S:81 E:88 ||| RB
guaranteed  ||| S:88 E:99 ||| VBN
and  ||| S:99 E:103 ||| CC
once  ||| S:103 E:108 ||| RB
fibrous  ||| S:108 E:116 ||| JJ
encapsulation  ||| S:116 E:130 ||| NN
occurs  ||| S:130 E:137 ||| VBZ
clinicians  ||| S:137 E:148 ||| RB
have  ||| S:148 E:153 ||| VB
few  ||| S:153 E:157 ||| JJ
options  ||| S:157 E:165 ||| NNS
other  ||| S:165 E:171 ||| JJ
than  ||| S:171 E:176 ||| IN
implant  ||| S:176 E:184 ||| JJ
removal ||| S:184 E:191 ||| NN
.  ||| S:191 E:193 ||| .
Our  ||| S:193 E:197 ||| PRP$
goal  ||| S:197 E:202 ||| NN
was  ||| S:202 E:206 ||| VBD
to  ||| S:206 E:209 ||| TO
test  ||| S:209 E:214 ||| VB
whether  ||| S:214 E:222 ||| IN
a  ||| S:222 E:224 ||| DT
WNT  ||| S:224 E:228 ||| NNP
protein  ||| S:228 E:236 ||| NN
therapeutic  ||| S:236 E:248 ||| NNS
could  ||| S:248 E:254 ||| MD
rescue  ||| S:254 E:261 ||| VB
such  ||| S:261 E:266 ||| JJ
failed  ||| S:266 E:273 ||| JJ
implants ||| S:273 E:281 ||| NN
.  ||| S:281 E:283 ||| .
Titanium  ||| S:283 E:292 ||| NNP
implants  ||| S:292 E:301 ||| NN
were  ||| S:301 E:306 ||| VBD
placed  ||| S:306 E:313 ||| VBN
in  ||| S:313 E:316 ||| IN
over-sized  ||| S:316 E:327 ||| JJ
murine  ||| S:327 E:334 ||| JJ
oral  ||| S:334 E:339 ||| JJ
osteotomies ||| S:339 E:350 ||| NN
.  ||| S:350 E:352 ||| .
A  ||| S:352 E:354 ||| DT
lack  ||| S:354 E:359 ||| NN
of  ||| S:359 E:362 ||| IN
primary  ||| S:362 E:370 ||| JJ
stability  ||| S:370 E:380 ||| NN
was  ||| S:380 E:384 ||| VBD
verified  ||| S:384 E:393 ||| VBN
by  ||| S:393 E:396 ||| IN
mechanical  ||| S:396 E:407 ||| JJ
testing ||| S:407 E:414 ||| NN
.  ||| S:414 E:416 ||| .
Interfacial  ||| S:416 E:428 ||| JJ
strains  ||| S:428 E:436 ||| NNS
were  ||| S:436 E:441 ||| VBD
estimated  ||| S:441 E:451 ||| VBN
by  ||| S:451 E:454 ||| IN
finite  ||| S:454 E:461 ||| JJ
element  ||| S:461 E:469 ||| NN
modeling  ||| S:469 E:478 ||| NN
and  ||| S:478 E:482 ||| CC
histology  ||| S:482 E:492 ||| VB
coupled  ||| S:492 E:500 ||| VBN
with  ||| S:500 E:505 ||| IN
histomorphometry  ||| S:505 E:522 ||| NN
confirmed  ||| S:522 E:532 ||| VBD
the  ||| S:532 E:536 ||| DT
lack  ||| S:536 E:541 ||| NN
of  ||| S:541 E:544 ||| IN
peri-implant  ||| S:544 E:557 ||| JJ
bone ||| S:557 E:561 ||| NN
.  ||| S:561 E:563 ||| .
After  ||| S:563 E:569 ||| IN
fibrous  ||| S:569 E:577 ||| JJ
encapsulation  ||| S:577 E:591 ||| NN
was  ||| S:591 E:595 ||| VBD
established  ||| S:595 E:607 ||| VBN
peri-implant  ||| S:607 E:620 ||| JJ
injections  ||| S:620 E:631 ||| NNS
of  ||| S:631 E:634 ||| IN
a  ||| S:634 E:636 ||| DT
liposomal  ||| S:636 E:646 ||| JJ
formulation  ||| S:646 E:658 ||| NN
of  ||| S:658 E:661 ||| IN
WNT3A  ||| S:661 E:667 ||| CD
protein  ||| S:667 E:675 ||| NN
( ||| S:675 E:676 ||| -LRB-
L-WNT3A ||| S:676 E:683 ||| NNP
)  ||| S:683 E:685 ||| -RRB-
or  ||| S:685 E:688 ||| CC
liposomal  ||| S:688 E:698 ||| JJ
PBS  ||| S:698 E:702 ||| NNP
( ||| S:702 E:703 ||| -LRB-
L-PBS ||| S:703 E:708 ||| NNP
)  ||| S:708 E:710 ||| -RRB-
were  ||| S:710 E:715 ||| VBD
then  ||| S:715 E:720 ||| RB
initiated ||| S:720 E:729 ||| VBN
.  ||| S:729 E:731 ||| .
Quantitative  ||| S:731 E:744 ||| JJ
assays  ||| S:744 E:751 ||| NN
were  ||| S:751 E:756 ||| VBD
employed  ||| S:756 E:765 ||| VBN
to  ||| S:765 E:768 ||| TO
analyze  ||| S:768 E:776 ||| VB
the  ||| S:776 E:780 ||| DT
effects  ||| S:780 E:788 ||| NNS
of  ||| S:788 E:791 ||| IN
L-WNT3A  ||| S:791 E:799 ||| CD
treatment ||| S:799 E:808 ||| NN
.  ||| S:808 E:810 ||| .
Implants  ||| S:810 E:819 ||| NNP
in  ||| S:819 E:822 ||| IN
gap-type  ||| S:822 E:831 ||| JJ
interfaces  ||| S:831 E:842 ||| NNS
exhibited  ||| S:842 E:852 ||| VBP
high  ||| S:852 E:857 ||| JJ
interfacial  ||| S:857 E:869 ||| JJ
strains  ||| S:869 E:877 ||| NNS
and  ||| S:877 E:881 ||| CC
no  ||| S:881 E:884 ||| DT
primary  ||| S:884 E:892 ||| JJ
stability ||| S:892 E:901 ||| NN
.  ||| S:901 E:903 ||| .
After  ||| S:903 E:909 ||| IN
verification  ||| S:909 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
implant  ||| S:925 E:933 ||| JJ
failure ||| S:933 E:940 ||| NN
,  ||| S:940 E:942 ||| ,
L-WNT3A  ||| S:942 E:950 ||| NNP
or  ||| S:950 E:953 ||| CC
L-PBS  ||| S:953 E:959 ||| JJ
injections  ||| S:959 E:970 ||| NNS
were  ||| S:970 E:975 ||| VBD
initiated ||| S:975 E:984 ||| VBN
.  ||| S:984 E:986 ||| .
L-WNT3A  ||| S:986 E:994 ||| NNP
induced  ||| S:994 E:1002 ||| VBD
a  ||| S:1002 E:1004 ||| DT
rapid ||| S:1004 E:1009 ||| JJ
,  ||| S:1009 E:1011 ||| ,
significant  ||| S:1011 E:1023 ||| JJ
increase  ||| S:1023 E:1032 ||| NN
in  ||| S:1032 E:1035 ||| IN
Wnt  ||| S:1035 E:1039 ||| NNP
responsiveness  ||| S:1039 E:1054 ||| NN
in  ||| S:1054 E:1057 ||| IN
the  ||| S:1057 E:1061 ||| DT
peri-implant  ||| S:1061 E:1074 ||| JJ
environment ||| S:1074 E:1085 ||| NN
,  ||| S:1085 E:1087 ||| ,
cell  ||| S:1087 E:1092 ||| NN
proliferation ||| S:1092 E:1105 ||| NN
,  ||| S:1105 E:1107 ||| ,
and  ||| S:1107 E:1111 ||| CC
osteogenic  ||| S:1111 E:1122 ||| JJ
protein  ||| S:1122 E:1130 ||| NN
expression ||| S:1130 E:1140 ||| NN
.  ||| S:1140 E:1142 ||| .
The  ||| S:1142 E:1146 ||| DT
amount  ||| S:1146 E:1153 ||| NN
of  ||| S:1153 E:1156 ||| IN
peri-implant  ||| S:1156 E:1169 ||| JJ
bone  ||| S:1169 E:1174 ||| NN
and  ||| S:1174 E:1178 ||| CC
bone  ||| S:1178 E:1183 ||| NN
in  ||| S:1183 E:1186 ||| IN
contact  ||| S:1186 E:1194 ||| NN
with  ||| S:1194 E:1199 ||| IN
the  ||| S:1199 E:1203 ||| DT
implant  ||| S:1203 E:1211 ||| NN
were  ||| S:1211 E:1216 ||| VBD
significantly  ||| S:1216 E:1230 ||| RB
higher  ||| S:1230 E:1237 ||| JJR
in  ||| S:1237 E:1240 ||| IN
L-WNT3A  ||| S:1240 E:1248 ||| CD
cases ||| S:1248 E:1253 ||| NNS
.  ||| S:1253 E:1255 ||| .
These  ||| S:1255 E:1261 ||| DT
data  ||| S:1261 E:1266 ||| NNS
demonstrate  ||| S:1266 E:1278 ||| VBP
L-WNT3A  ||| S:1278 E:1286 ||| RB
can  ||| S:1286 E:1290 ||| MD
induce  ||| S:1290 E:1297 ||| VB
peri-implant  ||| S:1297 E:1310 ||| JJ
bone  ||| S:1310 E:1315 ||| NN
formation  ||| S:1315 E:1325 ||| NN
even  ||| S:1325 E:1330 ||| RB
in  ||| S:1330 E:1333 ||| IN
cases  ||| S:1333 E:1339 ||| NNS
where  ||| S:1339 E:1345 ||| WRB
fibrous  ||| S:1345 E:1353 ||| JJ
encapsulation  ||| S:1353 E:1367 ||| JJ
predominates ||| S:1367 E:1379 ||| NN
.  ||| S:1379 E:1381 ||| .
This  ||| S:1381 E:1386 ||| DT
article  ||| S:1386 E:1394 ||| NN
is  ||| S:1394 E:1397 ||| VBZ
protected  ||| S:1397 E:1407 ||| VBN
by  ||| S:1407 E:1410 ||| IN
copyright ||| S:1410 E:1419 ||| NN
.  ||| S:1419 E:1421 ||| .
All  ||| S:1421 E:1425 ||| DT
rights  ||| S:1425 E:1432 ||| NNS
reserved ||| S:1432 E:1440 ||| VBN
.  ||| S:1440 E:1442 ||| .
